Overview
Availability
- Dr Mark Effron is:
- Available for supervision
Works
Search Professor Mark Effron’s works on UQ eSpace
2000
Journal Article
Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients
Mak, KH, Effron, MB and Moliterno, DJ (2000). Platelet glycoprotein IIb/IIIa receptor antagonists and their use in elderly patients. Drugs & Aging, 16 (3), 179-187. doi: 10.2165/00002512-200016030-00003
1999
Journal Article
Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study
Makkar, R, Goff, B, Eigler, N, Sebastian, M, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1999). Effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. Catheterization and Cardiovascular Interventions, 48 (4), 430-434. doi: 10.1002/(SICI)1522-726X(199912)48:43.0.CO;2-G
1999
Conference Publication
Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention
Marks, DS, Effron, MB, Mensah, GA, Fitzpatrick, SE, Tcheng, JE and Kereiakes, DF (1999). Abciximab markedly reduces 30-day adverse outcomes in black patients undergoing coronary intervention. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
1999
Journal Article
Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty
Brener, SJ, Barr, LA, Burchenal, JEB, Wolski, KE, Effron, MB and Topol, EJ (1999). Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. American Journal of Cardiology, 84 (6), 728-+. doi: 10.1016/S0002-9149(99)00421-X
1999
Journal Article
Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study)
Ellis, SG, Effron, MB, Gold, HK, Leon, MB, Popma, JJ, Serruys, PWJC, Colombo, A, Cohen, N, Juran, N, Werner, W, Heuser, RR, Spooner, S, Rihal, CS, Fox, R, Leon, MB, Brennan, J, Ricci, D, Fox, R, Teirstein, PS, Norman, S, Morris, N, Zidar, J and Rund, M (1999). Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation, 100 (8), 799-806.
1999
Journal Article
Readministration of abciximab: Interim report of the ReoPro Readministration Registry
Tcheng, JE, Kereiakes, DJ, Braden, GA, Jordan, RE, Mascelli, MA, Langrall, MA and Effron, MB (1999). Readministration of abciximab: Interim report of the ReoPro Readministration Registry. American Heart Journal, 138 (1), S33-S38. doi: 10.1053/hj.1999.v138.99236
1999
Journal Article
Rapport? Reply
Brener, SJ, Topol, EJ, Moliterno, DJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW and Effron, MB (1999). Rapport? Reply. Circulation, 99 (25), 3324-3324.
1998
Journal Article
Abciximab and alveolar hemorrhage - reply
Cohen, SA and Effron, MB (1998). Abciximab and alveolar hemorrhage - reply. New England Journal of Medicine, 339 (25), 1862-1863.
1998
Conference Publication
Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial
Brener, SJ, Barr, LA, Burcehnal, JEB, Katz, S and Effron, MB (1998). Provisional stenting improves outcome of primary angioplasty independently of the use of Abciximab. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
1998
Conference Publication
Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial
Brener, SJ, Cannata, RK, Effron, MB and Topol, NJ (1998). Critical effect of timing of abciximab bolus relative to first balloon inflation in primary angioplasty. The RAPPORT trial. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
1998
Conference Publication
Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct size
Brener, SJ, Cannata, RK and Effron, MB (1998). Abciximab accelerates the reperfusion process after primary angioplasty for acute myocardial infarction, without affecting enzymatic infarct size. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
1998
Conference Publication
Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3)
Tcheng, JE, Kereiakes, DJ, Braden, GA, Lincoff, AM, Mascelli, MA, Langrall, MA, Damaraju, LV, Schantz, AR, Barnathan, ES and Effron, MB (1998). Safety of abciximab retreatment - Final clinical report of the ReoPro readministration registry (R-3). PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
1998
Conference Publication
The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study
Makkar, R, Goff, B, Eigler, N, Fischell, T, Barr, L, D'Haem, C, Shah, PK, Effron, MB and Litvack, F (1998). The effect of glycoprotein IIb/IIIa inhibition without thrombolytic therapy on reperfusion in acute myocardial infarction: Results of ReoMI pilot study. NEW YORK: EXCERPTA MEDICA INC.
1998
Journal Article
Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction
Brener, SJ, Barr, LA, Burchenal, JEB, Katz, S, George, BS, Jones, AA, Cohen, ED, Gainey, PC, White, HJ, Cheek, HB, Moses, JW, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation, 98 (8), 734-741. doi: 10.1161/01.CIR.98.8.734
1998
Conference Publication
Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial
Barr, LA, Brener, SJ, Jones, AA, Moliterno, DJ, Effron, MB and Topol, EJ (1998). Abciximab reduces the need for bail-out stenting during primary angioplasty. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84737-7
1998
Conference Publication
Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT
Brener, SJ, Ellis, SG, Burchenal, JEB, Katz, S, Effron, MB and Topol, EJ (1998). Evidence for enrollment selection bias in trials of primary angioplasty: Comparison of GUSTO IIb and RAPPORT. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84709-2
1998
Conference Publication
Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial
Brener, SJ, Barr, LA, Cohen, ED, White, HJ, Moliterno, DJ, Cheek, HB, Effron, MB and Topol, EJ (1998). Abciximab reduces urgent target vessel revascularization at 30 days after primary angioplasty, independently of acute angiographic results. The RAPPORT trial. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83942-3
1998
Conference Publication
Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3)
Tcheng, JE, Kereiakes, DJ, George, BS, Braden, G, Langrall, MA, Zelinger, D, Jordan, R and Effron, MB (1998). Safety of readministration of abciximab; Interim results of the ReoPro readministration registry (R-3). NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)83944-7
1998
Conference Publication
Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting
Kleiman, NS, Graziadei, N, Lance, E, Maresh, K, Taylor, J, Higginbotham, J, Edwards, A, Effron, MB, Mascelli, MA and Jordan, RE (1998). Synergy of abciximab and ticlopidine in patients undergoing intracoronary stenting. NEW YORK: ELSEVIER SCIENCE INC. doi: 10.1016/S0735-1097(97)84740-7
1997
Conference Publication
Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results
Ellis, SG, Serruys, PW, Popma, JJ, Teirstein, PS, Ricci, DR, Gold, HK and Effron, MB (1997). Can abciximab prevent neointimal proliferation in Palmaz-Schatz stents? The final ERASER results. DALLAS: AMER HEART ASSOC.
Supervision
Availability
- Dr Mark Effron is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Media
Enquiries
For media enquiries about Dr Mark Effron's areas of expertise, story ideas and help finding experts, contact our Media team: